248 related articles for article (PubMed ID: 21243324)
21. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y
Surg Today; 2018 Oct; 48(10):952-962. PubMed ID: 29770847
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential.
Nakamura K; Sho M; Akahori T; Nishiwada S; Kunishige T; Nakagawa K; Nagai M; Takagi T; Terai T; Ikeda N
Pancreatology; 2021 Apr; 21(3):573-580. PubMed ID: 33541781
[TBL] [Abstract][Full Text] [Related]
23. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Pancreas; 2021 May-Jun 01; 50(5):744-750. PubMed ID: 34016892
[TBL] [Abstract][Full Text] [Related]
24. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
[TBL] [Abstract][Full Text] [Related]
26. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
[TBL] [Abstract][Full Text] [Related]
27. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
[TBL] [Abstract][Full Text] [Related]
29. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.
Eto K; Kawakami H; Kuwatani M; Kudo T; Abe Y; Kawahata S; Takasawa A; Fukuoka M; Matsuno Y; Asaka M; Sakamoto N
Br J Cancer; 2013 Apr; 108(7):1488-94. PubMed ID: 23492684
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
Bao PQ; Ramanathan RK; Krasinkas A; Bahary N; Lembersky BC; Bartlett DL; Hughes SJ; Lee KK; Moser AJ; Zeh HJ
Ann Surg Oncol; 2011 Apr; 18(4):1122-9. PubMed ID: 21104328
[TBL] [Abstract][Full Text] [Related]
31. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Elander NO; Aughton K; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Campbell F; Costello E; Halloran CM; Mackey JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Anthoney A; Lerch MM; Mayerle J; Oláh A; Büchler MW; Greenhalf W;
Br J Cancer; 2018 Apr; 118(7):947-954. PubMed ID: 29515256
[TBL] [Abstract][Full Text] [Related]
32. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
Colbert LE; Petrova AV; Fisher SB; Pantazides BG; Madden MZ; Hardy CW; Warren MD; Pan Y; Nagaraju GP; Liu EA; Saka B; Hall WA; Shelton JW; Gandhi K; Pauly R; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS
Cancer Res; 2014 May; 74(10):2677-87. PubMed ID: 24626090
[TBL] [Abstract][Full Text] [Related]
33. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Kadera BE; Toste PA; Wu N; Li L; Nguyen AH; Dawson DW; Donahue TR
Clin Cancer Res; 2015 Jan; 21(1):157-65. PubMed ID: 25348515
[TBL] [Abstract][Full Text] [Related]
34. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
Phua LC; Goh S; Tai DWM; Leow WQ; Alkaff SMF; Chan CY; Kam JH; Lim TKH; Chan ECY
Cancer Chemother Pharmacol; 2018 Feb; 81(2):277-289. PubMed ID: 29196965
[TBL] [Abstract][Full Text] [Related]
35. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Liang C; Shi S; Meng Q; Liang D; Ji S; Zhang B; Qin Y; Xu J; Ni Q; Yu X
Cell Mol Life Sci; 2018 Mar; 75(6):1001-1012. PubMed ID: 28993833
[TBL] [Abstract][Full Text] [Related]
36. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
38. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
[TBL] [Abstract][Full Text] [Related]
39. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M
Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570
[TBL] [Abstract][Full Text] [Related]
40. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
